Organization
Tulane Cancer Center
4 abstracts
Abstract
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).Org: Froedtert & Medical College of Wisconsin Cancer Center, Tulane Cancer Center, Tulane University Schoool of Medicine, Universitätsklinikum Carl Gustav Carus Dresden,
Abstract
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.Org: BC Cancer-Vancouver Centre, Vancouver Prostate Centre, Tulane Cancer Center, Gustave Roussy Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.Org: Tulane University, New Orleans, LA, Tempus Labs, Inc., Tulane Cancer Center,
Abstract
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Bon Secours St Francis Health System, University General Hospital Attikon, University Hospitals Seidman Cancer Center, CHU Angers,